Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics (Nasdaq: OVID) announced that management will participate in two June 2026 investor conferences focused on neurology.
Events include the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 p.m. and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15, with live and archived webcasts via its investor website.
Ovid Therapeutics (Nasdaq: OVID) appointed physician-scientist and biotech entrepreneur Anna Greka, M.D., Ph.D. to its Board of Directors, effective June 15, 2026. She will Chair the new Science and Technology Committee and join the Compensation Committee.
Greka leads Ladders to Cures, is a Core Institute Member and executive leader at the Broad Institute, and Professor of Medicine at Harvard Medical School and Mass General Brigham. She has founded and advised multiple biotech companies, including ventures whose assets were acquired by Bristol Myers Squibb and AstraZeneca.
Ovid Therapeutics (Nasdaq: OVID) reported Q1 2026 business and financial updates, highlighting pipeline progress and strengthened capital.
OV329 showed favorable safety up to 9 mg and is moving into Phase 2 studies in treatment‑resistant epilepsies and new pediatric programs. OV4071, an oral KCC2 activator, began Phase 1 dosing. Recent PIPE financings and warrant exercises raised about $113.9 million, bringing cash and securities to $165.6 million on March 31, 2026 and extending projected runway into 2029. Q1 net loss was $17.0 million on operating expenses of $17.8 million.
Ovid Therapeutics (Nasdaq: OVID) will host a KCC2 Deep Dive R&D event on Tuesday, April 14, 2026 at 9:30 am ET in New York, with a simultaneous webcast. The session will review Ovid's first-in-class KCC2 portfolio, pharmacodynamic data, translational and clinical strategy, and market potential.
Speakers include CEO Meg Alexander, independent clinicians, translational experts, and leading neuroscientists; a webcast replay will be archived for 90 days.
Ovid Therapeutics (Nasdaq: OVID) reported new safety and PK data for OV329 (7 mg) supporting dose selection and potential best-in-category profile, announced expansion into tuberous sclerosis complex seizures and infantile spasms funded by a $60.0M private placement, and cleared OV4071 Phase 1 in Australia.
The company held $90.4M at year-end 2025, expects Phase 2 OV329 to start Q2 2026, and noted potential $53.9M from Series A warrant exercise that could extend runway into 2029.
Ovid Therapeutics (Nasdaq: OVID) announced a $60.0 million PIPE financing expected to close on or about March 19, 2026. The financing is led by Point72 and includes existing investors.
The company is selling 19,154,321 common shares at $2.01 and pre-funded warrants to purchase 10,701,710 shares at $2.009 each, with an exercise price of $0.001. Net proceeds will support expansion of OV329 into tuberous sclerosis complex and infantile spasms and general R&D; placement agents include Leerink, Oppenheimer & Co. and LifeSci Capital. Registration rights for resale were agreed with investors.
Ovid Therapeutics (Nasdaq: OVID) said management will present at three investor conferences between Feb 25 and Mar 11, 2026, with scheduled times listed for each event.
A live webcast will be available at the company’s Events & Presentations page and an archived replay will be posted for about 30 days.
Ovid Therapeutics (NASDAQ: OVID) reported Phase 1 results for OV350, the first-ever KCC2 direct activator dosed in humans. The randomized, placebo-controlled single-ascending dose study in 16 healthy participants met primary objectives for safety, tolerability, and pharmacokinetics. No treatment-related serious adverse events were reported and pharmacokinetics matched predictions. Exploratory qEEG showed central activity consistent with expected KCC2 modulation and brain exposure. The IV program will not advance further; Ovid is prioritizing oral KCC2 activators, including OV4071 (20-fold more potent than OV350) with a regulatory filing targeted in Q1 2026 and clinical start planned for Q2 2026.
Ovid Therapeutics (NASDAQ: OVID) appointed Dr. Petra Kaufmann as Chief Medical Officer effective December 2, 2025. Dr. Kaufmann will lead clinical, medical, and regulatory strategy as Ovid advances its clinical pipeline, including next-generation GABA-AT inhibitor OV329 and a portfolio of first-in-class KCC2 direct activators.
She brings experience across industry and government, including leadership roles at Vigil Neuroscience, Affinia Therapeutics, Novartis Gene Therapies and the NIH, and played a key role in development and global approvals of Zolgensma. Her background emphasizes patient-focused trial design, biomarkers, and quantitative clinical planning.
Ovid Therapeutics (NASDAQ: OVID) announced a CEO succession: Meg Alexander will become CEO effective Jan 1, 2026, with Dr. Jeremy Levin transitioning to Executive Chair. The company reported positive Phase 1 biomarker results for OV329 showing strong GABA-AT inhibition and no treatment-related ocular safety findings, and plans a Phase 2a start in Q2 2026. First-in-human data for the IV KCC2 activator OV350 is expected in Q4 2025, and the oral KCC2 activator OV4071 IND is planned for Q1 2026 with a Phase 1/1b start in Q2 2026. Financially, cash and equivalents were $25.6M as of Sept 30, 2025, augmented by an $81M initial private placement, and the company expects funding into 2H 2028. Q3 2025 results: R&D $5.9M, G&A $6.8M, total operating expenses $12.7M, net loss $12.2M ($0.17 per share).